An interventional study of Microneedling and Trichloroacetic acid peel in Nonmelanoma Skin Cancer and Actinic Keratosis, sponsored by VA Office of Research and Development. Not yet recruiting at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Keratosis, Actinic with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Keratosis, Actinic · United States.
Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 66th largest by planned enrollment of the 152 interventional ones that give a count, is one of 11 that started in 2026, is one of 22 with no phase, reaches primary completion later than 18 of the 20 other live ones, and was the 162nd registered.
343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.
Browse Keratosis, Actinic studies →16 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Sun Pharmaceutical Industries Limited · Sites in United States
Ages 18–85
Marissa Lobl · Sites in United States
Ages 18+
Avant Health LLC · Sites in United States
Ages 18+
West Virginia University · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 44 · Phase 3 46 · Phase 4 17
First in 1996; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 73 across the 152 interventional studies, 117 across the 11 observational. Of the 136 that completed or were terminated, 78 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 165 have an industry lead sponsor. The 10 most frequent:
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
VA Office of Research and Development has 3 studies filed under Keratosis, Actinic — fewer than ten, so there is no comparison to draw.
7 of the studies in Keratosis, Actinic with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07729579Sun Pharmaceutical Industries LimitedAn Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face | 2026-12 |
| NCT05699603University of ArizonaTesting the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients | 2027-02-01 |
| NCT07286318Marissa LoblA Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | 2027-05-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 165 studies in Keratosis, Actinic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators' previous studies demonstrate geriatric subject skin responds differently to ultraviolet B (UVB) light compared to young subject skin, which contribute to increased rates of nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) development in geriatric populations. Previously, the investigators have shown that therapeutic dermal remodeling interventions (e.g., fractionated laser resurfacing and microneedling) can restore appropriate skin responses to UVB in geriatric skin. The investigators also demonstrated fractionated laser resurfacing (FLR) reduced rates of NMSC and AK development (compared to untreated control skin) in at risk geriatric subjects.
This interventional study will assess the ability of two therapeutic dermal remodeling therapies, microneedling and trichloroacetic acid chemical (TCA) peel, to impact NMSC and AK development in at risk geriatric subjects. Geriatric subjects will be enrolled into one of two study groups. In the first group, one arm will be treated with microneedling and the other arm will not be treated on day 1. In the second group, one arm will be treated with TCA peel and the other arm will not be treated on day 1. Subjects will subsequently be monitored for number of NMSC and AK on treated and untreated (control) forearms in each group. In addition to monitoring NMSC and AK development, subjects at the Richard L. Roudebush VAMC will undergo skin punch biopsy at one of their follow up visits for microscopic and molecular analyses of treated and untreated skin.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Forearm treatment with microneedling
Other: Microneedling
Forearm treatment with microneedling
Other: Microneedling
Forearm treatment with trichloroacetic acid peel
Other: Trichloroacetic acid peel
Forearm treatment with trichloroacetic acid peel
Other: Trichloroacetic acid peel
Microneedling- a mechanical tool that makes tiny holes in a superficial part of the skin
Trichloroacetic acid peel that removes a superficial part of the skin
Change From Baseline in the Number of Actinic Keratosis due to treatment.
Investigator will assess the number of actinic keratosis on both forearms
Time frame: up to 4 years
Change From Baseline in the Number Non-Melanoma Skin Cancers due to treatment.
Investigator will assess the number of nonmelanoma skin cancers on both forearms.
Time frame: up to 4 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Sep 2030, 46 months later.
Of 33 interventional studies with no phase under Keratosis, Actinic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's planned 46 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →